Complex Injectable Market Report 2025

The complex injectable market size has grown rapidly in recent years. It will grow from $17.7 billion in 2024 to $19.77 billion in 2025 at a compound annual growth rate (CAGR) of 11.7%. The growth during the historic period is linked to increasing prevalence of chronic diseases, rising demand for targeted biologic therapies, growing adoption of self-administration devices, expanding applications in oncology, and higher regulatory approvals for biosimilars.

The complex injectable market size is expected to see rapid growth in the next few years. It will grow to $30.38 billion in 2029 at a compound annual growth rate (CAGR) of 11.3%. The growth projected for the forecast period is driven by growing focus on personalized medicine, increasing healthcare expenditure, expanding applications in autoimmune disorders, rising patient preference for minimally invasive treatments, and higher demand for self-administration devices. Primary trends during the forecast period include advancements in biologic therapies, technological innovations in drug delivery systems, developments in nanotechnology for targeted delivery, improvements in cold chain logistics, and progress in injectable peptide and protein therapeutics.

The rising prevalence of chronic diseases is expected to drive growth in the complex injectable market in the coming years. Chronic diseases are long-term medical conditions that generally progress slowly and require continuous management. Factors such as aging populations contribute to this increase, as older adults are more prone to conditions such as diabetes, heart disease, and arthritis. Complex injectables aid in managing these chronic illnesses by delivering targeted medications that help control symptoms and slow disease progression. For example, the Office for Health Improvement & Disparities (OHID), a UK-based public health agency, projects that the global number of adults living with diabetes will increase from 537 million in 2021 to 643 million by 2030. Thus, the growing burden of chronic diseases is driving demand in the complex injectable market.

Leading companies in drug delivery systems are focusing on innovations such as autoinjector dosage forms to improve patient convenience, enhance treatment adherence, ensure precise and safe drug administration, and facilitate effective delivery of complex biologic therapies. Autoinjectors are pre-filled, self-administered injection devices designed to safely and accurately deliver a specific medication dose, often used for biologics and other complex drugs. For instance, in January 2024, Taisho Pharmaceutical Co. Ltd., a Japan-based generic drug manufacturer, launched Nanozora 30 mg for subcutaneous injection. This patient-friendly device allows for easy self-administration and includes a needle-covering feature to prevent accidental needle sticks. It enables patients with rheumatoid arthritis to conveniently receive treatment once every four weeks, broadening Taisho’s treatment options beyond its existing syringe formulations.

In April 2024, Eli Lilly and Company, a US-based pharmaceutical giant, acquired Nexus Pharmaceuticals Inc. for an undisclosed sum. This acquisition expands Lilly’s parenteral (injectable) manufacturing capabilities by incorporating Nexus’s advanced sterile manufacturing facility. The move strengthens Lilly’s ability to meet increasing demand for complex injectable drugs and supports its robust pipeline targeting conditions such as diabetes, obesity, and migraine. Nexus Pharmaceuticals Inc. is a US-based firm specializing in the development and production of generic and specialty injectable medications.

Major players in the complex injectable market are Johnson & Johnson Pharmaceutical, Merck & Co. Inc., Pfizer Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Novo Nordisk, Takeda Pharmaceutical Company Limited, Amgen Inc., Boehringer Ingelheim GmbH, Baxter Healthcare Corporation, Fresenius Kabi, Sun Pharmaceutical Industries Ltd., Hikma Pharmaceuticals, Indivior PLC, Amphastar Pharmaceuticals Inc., Braun Melsungen AG, Ferring Pharmaceuticals, Oakwood Labs, ForDoz Pharma.

North America was the largest region in the complex injectable market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in complex injectable report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the complex injectable market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

Complex injectables refer to advanced pharmaceutical products that require sophisticated formulation and sterile manufacturing processes for injection. They are used to deliver targeted therapies, vaccines, or biologics directly into the body, addressing diseases that cannot be effectively treated with conventional oral medications.

The primary product types of complex injectables include monoclonal antibodies, gene therapies, vaccines, proteins and peptides, and antibody-drug conjugates (ADCs). Monoclonal antibodies are laboratory-produced molecules that mimic the immune system’s ability to recognize and bind specific antigens. They are applied across therapeutic areas such as oncology, diabetes, autoimmune disorders, neurological disorders, cardiovascular diseases, and infectious diseases. Routes of administration include intravenous (IV), subcutaneous (SC), intramuscular (IM), epidural, and intradermal. Distribution occurs through direct sales, pharmacies, e-commerce platforms, distributors, and wholesalers. Key end users include hospitals, ambulatory surgical centers, specialty clinics, home healthcare providers, and research institutions.

The complex injectable market research report is one of a series of new reports that provides complex injectable market statistics, including the complex injectable industry global market size, regional shares, competitors with the complex injectable market share, detailed complex injectable market segments, market trends, and opportunities, and any further data you may need to thrive in the complex injectable industry. This complex injectable market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The complex injectable market consists of sales of liposomal injections, depot injections, nanoparticle-based injectables, emulsions, and suspensions. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.